Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma - Younes, A; Gopal, AK; Smith, SE; Ansell, SM; Rosenblatt, JD; Savage, KJ; Ramchandren, R; Bartlett, NL; Cheson, BD; de Vos, S; Forero-Torres, A; Moskowitz, CH; Connors, JM; Engert, A; Larsen, EK; Kennedy, DA; Sievers, EL; Chen, R (J Clin Oncol., 2012)
.